Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Allon Therapeutics Inc NPCUF

Allon Therapeutics, Inc. is a Canada-based Company, which develops treatments for neurodegenerative diseases. The Company is engaged in pre-clinical and clinical development of proprietary neuroprotective compounds which may be applied for the potential treatment of Alzheimer's Disease, Parkinson's Disease, senile dementia, glaucoma, traumatic head injury, neuronal damage due to stroke and... see more

GREY:NPCUF - Post Discussion

Allon Therapeutics Inc > Cantor sells and Desjardins Securities buys...
View:
Post by Vimon66 on Oct 31, 2017 12:37pm

Cantor sells and Desjardins Securities buys...

Come on guys!!! What's the story? Who's behind all this?
Comment by flogshot on Nov 02, 2017 11:59am
It looks that the answer to this kind of trading could come on next wednesday, when they will report financial result. My feeling is good, because the price is holding well and the average volume is climbing... But i am worried about no news since 3 months.....
Comment by Vimon66 on Nov 02, 2017 6:00pm
I see you, but high volumes are on my opinion the sole results of institutional trading which seems to occured at prefixed prices. Plus, if there were really some takeover rumors going on, why would an institutional want to sell now and not wait. As a matter of facts, today's volume were historically normal and there was no weird trading taking place.
Comment by flogshot on Nov 02, 2017 8:38pm
I like Desjardins to buy because their analyst, Mr Poirier, had a projection of 1.80 $ for next year.  Cantor did not have any recommendation ion on Napec, as far as i know !!! i would be surprised to see more big volume before next week financial report. Only for October, we had approx 6 500 000 shares traded wich give an average of 300 000 shares a day, wich is 3 time the usual volume ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities